Search research articles
Contact Us
Filters
Showing results (321-330 of 338) with videos related to
Page
of 34
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 27, 2015
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
Ji Yun Lee, Jong-Mu Sun, Dong Ryul Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
JTO Clinical and Research Reports
|
December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
Elife
|
November 8, 2024
Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer
Nayoung Kim, Sehhoon Park, Areum Jo, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
The Lancet. Oncology
|
October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.
Cancer Research and Treatment
|
September 5, 2018
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
April 25, 2023
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells
Se-Hoon Lee, Yeongmin Kim, Bu-Nam Jeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2015
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 338) with videos related to
Sort By:
Page
of 34
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 27, 2015
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
Ji Yun Lee, Jong-Mu Sun, Dong Ryul Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
JTO Clinical and Research Reports
|
December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
Elife
|
November 8, 2024
Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer
Nayoung Kim, Sehhoon Park, Areum Jo, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
The Lancet. Oncology
|
October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.
Cancer Research and Treatment
|
September 5, 2018
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
April 25, 2023
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells
Se-Hoon Lee, Yeongmin Kim, Bu-Nam Jeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2015
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
Page
of 34